AAV based gene therapy (REGENXBIO/Neurimmune)

N/A

Report date: 2025/03/14 16:40:27

Base Information

Drug NameAAV based gene therapy (REGENXBIO/Neurimmune)
Drug Alias NameAAV-delivered therapeutic antibody (REGENXBIO/Neurimmune)
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionSynuclein alpha modulatorsMicrotubule-associated protein tau modulators
TargetsMicrotubule-associated protein tauSynuclein alpha
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegenxbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegenxbio IncNeurimmune Ag
Inactive CompaniesN/A
Active IndicationsNerve Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A